|Numéro de publication||WO1996013284 A1|
|Type de publication||Demande|
|Numéro de demande||PCT/GB1995/002542|
|Date de publication||9 mai 1996|
|Date de dépôt||30 oct. 1995|
|Date de priorité||28 oct. 1994|
|Numéro de publication||PCT/1995/2542, PCT/GB/1995/002542, PCT/GB/1995/02542, PCT/GB/95/002542, PCT/GB/95/02542, PCT/GB1995/002542, PCT/GB1995/02542, PCT/GB1995002542, PCT/GB199502542, PCT/GB95/002542, PCT/GB95/02542, PCT/GB95002542, PCT/GB9502542, WO 1996/013284 A1, WO 1996013284 A1, WO 1996013284A1, WO 9613284 A1, WO 9613284A1, WO-A1-1996013284, WO-A1-9613284, WO1996/013284A1, WO1996013284 A1, WO1996013284A1, WO9613284 A1, WO9613284A1|
|Inventeurs||Yimin Qin, Keith Dennis Gilding|
|Déposant||Innovative Technologies Limited|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (4), Citations hors brevets (1), Référencé par (12), Classifications (6), Événements juridiques (6)|
|Liens externes: Patentscope, Espacenet|
WOUND TREATMENT COMPOSITION
The present invention relates to compositions which are useful in the treatment
of wounds. The invention relates more particularly to such compositions which
incorporate O-carboxymethyl chitosan (OCC) or N-, O- carboxymethyl chitosan
(NOCC) which are a water soluble derivatives of chitin.
NOCC is a known material and its preparation is disclosed for example in US-
A-4,619,995. Briefly NOCC may be prepared by a solid phase reaction between
chitosan and monochloroacetic acid under alkaline conditions. The degree of
substitution can be varied but is typically 0.6 to 1.0. OCC may be produced by a similar
procedure effected to give a degree of substitution of 0.3-0.5.
According to a first aspect of the present invention there is provided a
composition for use in treating a wound comprising a hydrogel containing OCC or
NOCC and a plasticising compound.
Compositions in accordance with the invention are useful in the treatment of
cavity wounds, e.g. decubitus ulcers. The compositions are introduced into the wound
and pressed firmly into the base thereof. For preference the wound is then covered and
sealed by a film having a high MVTR, typically 3,000 to 12.000 g m"2 24hr"' (e.g.
hydroderm (ex Wilshire Medical) or IT425 or IT625 (ex Innovative Technologies)).
The compositions may also be used in the treatment of sinuses.
Preferred compositions in accordance with the invention have a viscosity in the
range 20,000 to 100,000 cP. Compositions in accordance with the invention will generally contain a
maximum of 5% by weight of OCC and/or NOCC. Typically the OCC or NOCC
content will be in the range 2-4%.
The plasticiser will generally be present in a maximum amount of 20% by
weight, more usually in the range 2-20% by weight.
Examples of plasticiser include polyhydroxy compounds, e.g. glycerol, sorbitol,
propylene glycol, and polyethylene glycol (a preferred example of which is PEG 400).
The most preferred plasticiser glycerol.
The aqueous phase of the gel will for preference comprise isotonic buffered saline, e.g. phosphate buffered saline.
Additional components may be included in the composition to enhance their
healing properties. Examples include antimicrobial agents which may be used at a level
of 1-2% of the composition. A preferred anti-microbial agent is chlorhexidine
Antimicrobial properties may also be achieved by use of enzymes, e.g. glucose
oxidase/lactic acid peroxidase enzymes as a natural disinfection system activated by
glucose (present in exudate).
A further possibility is to include a component, e.g. pectin, which facilitates
wound debridement. This component may for example be used in an amount up to
20%, more preferably up to 10%, e.g. 0.05-1% by weight.
Compositions for use in accordance with the invention may be produced in
various ways. For example a composition may be produced by dissolving the required amounts of OCC or NOCC (e.g. 3-5%), plasticiser and any other components in
phosphate buffered saline at 90°C then cooling. The composition may be sterilised by
autoclaving at 120°C for 15 minutes.
The gels obtained may be incorporated into a convenient delivery system, e.g. a
syringe, sachet, tube or squeeze bottle, for introduction into a wound.
The invention is illustrated by the following non-limiting Example.
A gel was produced by dissolving 3-4% NOCC and 1 -2% high methoxy pectin
(Bulmers) in isotonic phosphate buffered saline at pH 7 with 2% glycerol. The gel was
filled into a vessel and autoclaved at 120°C for 15 minutes. The viscosity of the gel
reduced slightly during autoclaving but by no more than 10%.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|EP0356060A2 *||7 août 1989||28 févr. 1990||Minnesota Mining And Manufacturing Company||Wound filling compositions|
|EP0426368A2 *||24 oct. 1990||8 mai 1991||Howmedica Inc.||Compositions containing derivatives of chitin for preventing adhesion|
|US3903268 *||19 févr. 1971||2 sept. 1975||Lescarden Ltd||Chitin and chitin derivatives for promoting wound healing|
|US4659700 *||2 mars 1984||21 avr. 1987||Johnson & Johnson Products, Inc.||Chitosan-glycerol-water gel|
|1||*||R.A.A.MUZZARELLI ET AL.: "N-CARBOXYBUTYL CHITOSAN AND FIBRIN GLUE IN CUTANEOUS REPAIR PROCESSES", JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 5, no. 4, US, pages 396 - 410, XP000213548|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|WO1997003710A1 *||19 juil. 1996||6 févr. 1997||Innovative Technologies Limited||Wound treatment composition|
|WO1998050050A1 *||4 mai 1998||12 nov. 1998||Chitogenics, Inc.||Covalently linked n,o-carboxymethylchitosan and uses thereof|
|WO2006034688A1 *||23 sept. 2005||6 avr. 2006||Universität Hamburg||Method for the production of a wound pad|
|WO2015061606A1 *||23 oct. 2014||30 avr. 2015||Medtronic Xomed, Inc.||Chitosan stenting paste|
|US6124273 *||13 oct. 1997||26 sept. 2000||Chitogenics, Inc.||Chitin hydrogels, methods of their production and use|
|US6645947||20 mai 1999||11 nov. 2003||Chitogenics, Inc.||Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins|
|US6809085||6 juil. 2000||26 oct. 2004||Chitogenics, Inc.||Adherent N,O-Carboxymethylchitosan drug delivery devices for moist tissue and methods of their use|
|US6894035 *||25 sept. 2003||17 mai 2005||Chitogenics, Inc.||Adhesive N,O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins|
|US7238678 *||11 avr. 2005||3 juil. 2007||Chitogenics, Inc.||Adhesive N,O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins|
|US7265097||20 août 2002||4 sept. 2007||Chitogenics, Inc.||Methods of drug delivery using sulphated chitinous polymers|
|US9192574||30 juin 2014||24 nov. 2015||Medtronic Xomed, Inc.||Chitosan paste wound dressing|
|US9192692||24 oct. 2013||24 nov. 2015||Medtronic Xomed, Inc.||Chitosan stenting paste|
|Classification internationale||A61L26/00, A61L15/28|
|Classification coopérative||A61L15/28, A61L26/0023|
|Classification européenne||A61L15/28, A61L26/00B5|
|9 mai 1996||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN
|9 mai 1996||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
|27 juin 1996||DFPE||Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)|
|7 août 1996||121||Ep: the epo has been informed by wipo that ep was designated in this application|
|23 juil. 1997||122||Ep: pct application non-entry in european phase|
|25 sept. 1997||REG||Reference to national code|
Ref country code: DE
Ref legal event code: 8642